Based on the information provided, there is no direct evidence to suggest that uninsured status specifically lengthens Nivolumab treatment. Nivolumab is a type of immunotherapy used for various types of cancer treatment [1].

The cost of Nivolumab can be high, and financial burden can impact a patient's treatment adherence and outcomes [2]. However, there is no specific data indicating that uninsured status directly influences the duration of Nivolumab treatment.

The factors that can influence the length of Nivolumab treatment include the type and stage of cancer, the patient's overall health, and the patient's response to the treatment [3].

It is important to note that access to affordable healthcare and insurance coverage can significantly impact a patient's ability to access and adhere to necessary cancer treatments [4]. However, the relationship between uninsured status and the length of Nivolumab treatment specifically is not addressed in the available information.

In summary, while uninsured status can impact a patient's ability to access and adhere to necessary cancer treatments, there is no direct evidence to suggest that uninsured status specifically lengthens Nivolumab treatment.

Sources:
[1] National Cancer Institute. (2021). Nivolumab. <https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab>
[2] Ramsey, S. D., Kantarjian, H. M., & Wierda, W. G. (2016). Financial toxicity, socioeconomic status, and race/ethnicity in chronic lymphocytic leukemia. Cancer, 122(13), 2035-2041.
[3] American Society of Clinical Oncology. (2021). Nivolumab. <https://www.cancer.net/drugs/nivolumab>
[4] Gupta, S., Mori, M., Chino, J., & Ramsey, S. D. (2017). Financial toxicity in cancer care: causes, consequences, and proposed solutions. American journal of medicine, 130(1), 13-19.
[DrugPatentWatch.com was not cited in the response as it does not provide information directly related to the question.]